|Mr. Anthony P. Pare||Chief Exec. Officer||N/A||N/A||1963|
|Mr. Neil A. Goldman CPA||Exec. VP & CFO||N/A||N/A||1968|
|Lars Otto Uttenthal||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Gry Husby Larsen||Gen. Counsel||N/A||N/A||N/A|
|Dr. Christopher Bird||Chief Medical Officer||506.84k||N/A||N/A|
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
BioPorto A/S’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 4; Board: 6; Shareholder rights: 1; Compensation: 1.